Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — XOMA — Investor Presentation (January 2022)
25 slides from Xoma Royalty's investor presentation, January 2022
Slide 1: Corporate Presentation: A Royalty Aggregation Company
CORPORATE PRESENTATION A ROYALTY AGGREGATION JANUARY 2022 NASDAQ: XOMA COMPANY 1
Slide 2: Disclaimers
DISCLAIMERS Certain statements in this presentation are forward-looking statements Potential risks to XOMA meeting these expectations are described in within the meaning of Section 27A of the Securities Act of 1933 and more detail in XOMA's most recent filing on Form 10-K and in other Section 21E of
Slide 3: XOMA Snapshot
XOMA SNAPSHOT ▪ Portfolio of 70+ assets in >30 disclosed indications today and growing - Roche – faricimab1 - Novartis – NIS793, iscalimab, gevokizumab - Merck – MK-4830 - Bayer – osocimab - Janssen - cetrelimab ▪ Acquire drug royalties associated with mid- to early stage clinical candidates ₋ Diffe
Slide 4: XOMA's Portfolio: 70+ Partnered Programs
XOMA’S PORTFOLIO: 70+ PARTNERED PROGRAMS PRECLINICAL PHASE 1 PHASE 1/2 PHASE 2 PHASE 3 BLA FILING 1 2 22 Further 4 Development Expenses by XOMA: $0 18 10 >50% of assets with 15+ Large-Cap Partners 4
Slide 5: Since 2017 Strategic Pivot, Portfolio Has Seen >25 Advancements
SINCE 2017 STRATEGIC PIVOT, PORTFOLIO HAS SEEN >25 ADVANCEMENTS FROM PHASE TO PHASE PROGRAM ADVANCEMENTS SINCE 2017 Ph 2 to Ph 3 3 Ph 2a to Ph 2b 2 Ph 1 to Ph 2 10 Entered Clinic 12 5
Slide 6: Key XOMA Portfolio Assets
KEY XOMA PORTFOLIO ASSETS Asset Partner Royalty Rate Stage Faricimab1 Roche 0.5% BLA accepted by FDA NIS793 (anti-TGFβ) Novartis Mid-single-digit to low teens Phase 3 Iscalimab (anti-CD40) Novartis Mid-single-digit to low teens Phase 2 MK-4830 (anti-ILT-4) Merck Low single-digit Phase 2 Osocimab (an
Slide 7: Q3 2021 Results
Q3 2021 Results Investor presentation Disclaimer AY ss » 1 NOVARTIS | Reimagining Medicine
Slide 8: XOMA Royalty Rates
XOMA Royalty Rates: NIS793 Mid-single digit to low teens Iscalimab Mid-single digit to low teens VPM087 High-single digit to mid teens 8 NIR178 Low-single digits
Slide 9: Significant Number of Clinical Events – Recent and Future Expectations
SIGNIFICANT NUMBER OF CLINICAL EVENTS – RECENT AND FUTURE EXPECTATIONS SPONSOR/PROGRAM: Phase 1 Phase 2 Phase 3 Regulatory Roche / faricimab1 BLA accepted by FDA JNJ / cetrelimab Ph 3 initiation Novartis / NIS793 Ph 3 initiation Rezolute / RZ358 Ph 2 CHI readout Bayer / osocimab Ph 2 ESRD readout As
Slide 10: Who We Are
WHO WE ARE Board of Directors ▪ Leadership • Denny Van Ness Hidden Hill Advisors ▪ Jim Neal, CEO • Heather L. Franklin ▪ Tom Burns, CFO Blaze BioScience ▪ Business Development Team • Natasha Hernday Seattle Genetics ▪ Legal Team • Barbara Kosacz Kronos Bio ▪ Finance Team • Joe Limber ▪ Consultants S
Slide 11: XOMA Is Positioned to Monetize Royalties on Mid- to Early-Stage Clinical Assets
XOMA IS POSITIONED TO MONETIZE ROYALTIES ON MID- TO EARLY-STAGE CLINICAL ASSETS Capital per transaction $200M + Royalty Pharma $100M – DRI $200M Healthcare Trust $25M – Ligand $100M HCRP < $25M 11 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL COMMERCIAL
Slide 12: Basics of a XOMA Royalty Monetization Transaction
BASICS OF A XOMA ROYALTY MONETIZATION TRANSACTION STEP 2: STEP 1: BIG Program Licensed BIOTECH PHARMA Royalties & Milestones 12 12
Slide 13: Opportunities Abound for Royalty Monetization
OPPORTUNITIES ABOUND FOR TOTAL ROYALTY 3,817 INDUSTRY LICENSING MONETIZATION DEALS ’14 – ’20 PHASE 3 LICENSING DEALS: 514 Biotech & Pharma License Transactions consist of: PHASE 2 LICENSING DEALS: 646 • Milestone payments • Royalty obligations Companies’ funding PHASE 1 LICENSING DEALS: 457 needs in
Slide 14: Key Attributes of XOMA Target Assets
KEY ATTRIBUTES OF XOMA TARGET ASSETS STRONG DEVELOPER/MARKETER Assets partnered with high-quality pharma / biopharma companies Rx MID- TO EARLY STAGE CLINICAL ASSETS Therapeutic area agnostic LONG DURATION OF MARKET EXCLUSIVITY Patent expiration or regulatory exclusivity HIGH REVENUE POTENTIAL High
Slide 15: Acquired from Affitech SA: New Economic Rights Acquisition
XOMA NEW ECONOMICS RIGHTS ACQUISITION Roche's faricimab
Slide 16: XOMA Acquisition Transactions 2018 - 2021
XOMA ACQUISITION TRANSACTIONS 2018 - 2021 ASSETS COMPANY PARTNER / LICENSEE CAPITAL DEPLOYED THERAPEUTIC AREA ACQUIRED wAMD, DME, diabetic Affitech 1 $6M retinopathy Kuros 1 $7M Immuno-Oncology Viracta 2 $13.5M Oncology $15M Agenus 7 ($1M milestone Immuno-Oncology earned since) Aronora 5 $9M Thrombo
Slide 17: Financial Highlights
FINANCIAL HIGHLIGHTS ($M) Expenses YE Cash ($M) $100 $90 $90 $80 G&A non-cash $80 $70 G&A $70 $60 R&D non-cash $60 $50 $50 R&D Expense $40 $40 $30 $30 $20 $20 $10 $10 $0 $0 2015 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 17
Slide 18: Recent Highlights
RECENT HIGHLIGHTS PARTNERS & PARTNERED ASSETS ▪ Novartis OPERATIONAL ₋ Launched NIS793 (anti-TGFβ mAb) Phase 3 study in mPDAC; received Orphan Drug Designation for pancreatic cancer in combination with standard of care chemotherapy ▪ Acquired economic interest in Roche’s faricimab from ₋ Conducting
Slide 19: What Makes XOMA So Exciting
WHAT MAKES XOMA SO EXCITING ▪ XOMA holds potential royalty stream on 70+ assets; pharmaceutical partners fund 100% of research & development costs • Roche – faricimab1 • Novartis – NIS793, iscalimab, gevokizumab • Merck – MK-4830 • Bayer – osocimab • Janssen - cetrelimab ▪ XOMA sources royalty right
Slide 20: Corporate Presentation: A Royalty Aggregation Company
CORPORATE PRESENTATION A ROYALTY AGGREGATION JANUARY 2022 NASDAQ: XOMA COMPANY 20
Slide 21: We Expect a Significant Number of Clinical Events in the Next 12 Months
WE EXPECT A SIGNIFICANT NUMBER OF CLINICAL EVENTS IN THE NEXT 12 MONTHS As disclosed by partners in public filings Phase 1 Phase 1/2 Phase 2 Phase 3 Regulatory Bayer/osocimab - Incyte/INCAGN01876 – Rezolute/RZ358 – Novartis/NIS793 – Roche/faricimab1 ESRD completed advanced malignancies readout CHI r
Slide 22: XOMA's Portfolio: Key Mid-Late-Stage Highlights
XOMA’S PORTFOLIO: KEY MID-LATE-STAGE (Does not include all assets, including certain assets subject HIGHLIGHTS to confidentiality agreements) ASSET TARGET THERAPEUTIC AREA ROYALTY RATE STAGE angiopoietin-2 (Ang-2) and BLA accepted faricimab1 vascular growth factor-A Ophthalmology 0.5% by FDA (VEGF-A
Slide 23: XOMA's Portfolio: Key Mid-Late-Stage Highlights
XOMA’S PORTFOLIO: KEY MID-LATE-STAGE (Does not include all assets, including certain assets subject HIGHLIGHTS to confidentiality agreements) ASSET TARGET THERAPEUTIC AREA ROYALTY RATE STAGE MK-4830 ILT-4 Oncology Low single-digit Phase 2 mezagitamab (TAK-079) CD-38 Oncology 4% Phase 2 RZ358 INSR Co
Slide 24: XOMA's Portfolio: Mid-Stage
XOMA’S PORTFOLIO: MID-STAGE (Does not include all assets, including certain assets subject to confidentiality agreements) ASSET TARGET THERAPEUTIC AREA ROYALTY RATE STAGE AB002 (E-WE thrombin) E-WE thrombin Renal disease Low single-digit Phase 2 xisomab 3G3 (AB023) Factor XI Renal disease / thrombos
Slide 25: XOMA's Portfolio: Early Stage
XOMA’S PORTFOLIO: EARLY STAGE (Does not include all assets, including certain assets subject to confidentiality agreements) ASSET NAME TARGET THERAPEUTIC AREA ROYALTY RATE STAGE INCAGN1949 OX-40 Oncology Mid-single-digit Phase 1/2 INCAGN02390 TIM-3 Oncology Low to mid-single-digit Phase 1/2 INCAGN02